

Prevalence and Associated Factors of Urinary Tract Infection in Patients with Diabetic Neuropathy [Letter]

Qiu Wang, Xiuxian Huang, Wensheng Lu 

Department of Endocrinology and Metabolism, Guangxi Academy of Medical Sciences and the People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, 530021, People's Republic of China

Correspondence: Wensheng Lu, Email Lwsxwqz@163.com

Dear editor

Latterly, an original observational study titled “Prevalence and Associated Factors of Urinary Tract Infection in Patients with Diabetic Neuropathy: A Hospital-Based Cross-Sectional Study”¹ was published in *Diabetes, Metabolic Syndrome and Obesity-Targets and Therapy* by authors Wang et al. We congratulate and pay tribute to the authors.

This study mainly discussed the prevalence of urinary tract infection (UTI) and its influencing factors in patients with diabetic neuropathy. This study concluded that older age, female sex, hypodermic insulin injection, CKD, history of UTI, and positive urinary nitrite were independent risk factors for UTI in patients with diabetic neuropathy.

We consider four things that need further clarification. Firstly, unbalanced baseline data on the age and gender of enrolled individuals will inevitably impact statistical results. Secondly, lack of vital indicators of diabetic nephropathy in baseline data: urinary albumin creatinine ratio (UACR) and eGFR. According to the guidelines,^{2,3} when UACR >30 mg/g or eGFR ≥ 60 mL/min $\cdot 1.73$ m², sodium-dependent glucose transporters-2 inhibitor (SGLT-2i) should be used early in routine clinical practice. However, UTI usually may be the result of using SGLT-2i. Thirdly, lack of bone metabolism indicators such as bone mineral density (BMD). Older women with postmenopausal osteoporosis often lead to UTI.⁴ Fourthly, this study is a retrospective single-center cross-sectional observational study, and the number of enrolled cases is relatively small. The conclusion of this study still needs to be confirmed by randomized, double-blind, multicenter, and prospective longitudinal cohort studies.

Although this article has some shortcomings, its topics are essential for clinical practice and still serve as a guiding document for our clinical practice.

Disclosure

The authors report no conflicts of interest in this communication.

References

1. Wang X, Wang Y, Luo L, et al. Prevalence and associated factors of urinary tract infection in patients with diabetic neuropathy: a Hospital-Based Cross-Sectional Study. *Diabetes Metab Syndr Obes.* 2023;16:1261–1270. doi:10.2147/DMSO.S402156
2. American Diabetes Association Professional Practice Committee. Chronic kidney disease and risk management: standards of medical care in diabetes-2022. *Diabetes Care.* 2022;45:S175–S184. doi:10.2337/dc22-S011
3. de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). *Diabetes Care.* 2022;45(12):3075–3090. doi:10.2337/dc22-0027
4. Greendale GA, Lee NP, Arriola ER. The menopause. *Lancet.* 1999;353(9152):571–580. doi:10.1016/S0140-6736(98)05352-5

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Diabetes, Metabolic Syndrome and Obesity 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Diabetes, Metabolic Syndrome and Obesity editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Diabetes, Metabolic Syndrome and Obesity

Dovepress

Publish your work in this journal

Diabetes, Metabolic Syndrome and Obesity is an international, peer-reviewed open-access journal committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-journal>

<https://doi.org/10.2147/DMSO.S432048>